津药药业(600488) - 2025 Q2 - 季度业绩预告

Key Highlights The company anticipates a significant decline of 62.19% to 68.38% in net profit attributable to shareholders for the 2025 semi-annual period, with non-recurring net profit expected to decrease by 13.32% to 19.77% - This performance forecast applies to situations where profitability is achieved, but net profit has decreased by over 50% compared to the same period last year[3] 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (10,000 CNY) | Year-on-Year Change (10,000 CNY) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 4,490 - 5,370 | Decrease 8,832.02 - 9,712.02 | Decrease 62.19% - 68.38% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 11,200 - 12,100 | Decrease 1,859.05 - 2,759.05 | Decrease 13.32% - 19.77% | Current Period Performance Forecast This section details the performance forecast for January 1 to June 30, 2025, indicating a year-on-year decline in both net profit attributable to shareholders and non-recurring net profit, with the forecast being unaudited - The performance forecast period is from January 1, 2025, to June 30, 2025[4] 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (10,000 CNY) | Year-on-Year Change (10,000 CNY) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 4,490 - 5,370 | Decrease 8,832.02 - 9,712.02 | Decrease 62.19% - 68.38% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 11,200 - 12,100 | Decrease 1,859.05 - 2,759.05 | Decrease 13.32% - 19.77% | - The performance forecast presented herein is unaudited[4] Prior Period Performance This section presents the net profit attributable to shareholders, non-recurring net profit, and basic earnings per share for the 2024 semi-annual period, serving as the comparative baseline for the current forecast 2024 Semi-Annual Actual Performance | Metric | 2024 Semi-Annual Actual (10,000 CNY) | | :--- | :--- | | Net Profit Attributable to Shareholders | 14,202.02 | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 13,959.05 | | Basic Earnings Per Share | 0.130 CNY | Main Reasons for Performance Decline The anticipated performance decline is primarily due to multiple factors including centralized procurement, intensified international market competition, and administrative fines for monopolistic behavior, leading to a year-on-year decrease in sales revenue and profit - The company's sales revenue and profit experienced a certain degree of year-on-year decline this year, influenced by factors such as centralized procurement and intensified international market competition[7] - The pharmaceutical preparation business saw a year-on-year decrease in revenue and gross profit due to the impact of the tenth batch of centralized procurement, which led to a decline in the unit price of winning bid products[7] - The active pharmaceutical ingredient (API) business experienced a year-on-year decline in revenue and profit, as both sales volume and unit prices of some products decreased due to intensified market competition[7] - The company incurred an administrative fine of 69.1924 million CNY this year due to monopolistic behavior[7] Risk Warning The company declares that there are no significant uncertainties affecting the accuracy of this performance forecast - There are no significant uncertainties affecting the accuracy of this performance forecast[8] Other Explanatory Notes Investors are reminded that the forecast data is preliminary, and final financial figures will be based on the officially disclosed semi-annual report, with a caution regarding investment risks - The aforementioned forecast data represents preliminary calculations by the company's finance department[9] - Should there be a significant discrepancy between the disclosed performance forecast and actual results, the company will promptly issue a revised performance forecast announcement[9] - The specific and accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of investment risks[9]